Bioavailability of Eszopiclone 3.0 mg With Regards to Reference Product
Status:
Completed
Trial end date:
2022-04-19
Target enrollment:
Participant gender:
Summary
This study will investigate the bioavailability in fasting healthy, adult, human subjects of
1 tablet of two formulations containing Eszopiclone 3mg.
The study will be performed at a single site with 28 subjects. Participants will take 1
tablet of the test product 1, and 1 tablet of the test product 2, and reference product in 4
periods and 2 sequences (either test after reference or reference after test). There will be
a washout of at least 2 days between each study period.